ASLAN Release: Pharma Receives Approval To List On Taipei Exchange
Singapore and Taiwan, 23 January 2017 – ASLAN Pharmaceuticals (ASLAN; ticker: 6497), a biotech company focused on the development of immunotherapies and targeted agents for Asia prevalent tumour types, today announced that it has received approval from the Board of Taipei Exchange (“TPEx”) to list on TPEx.
ASLAN applied for the listing with Qualified Technology Enterprise (QTE) status with a paid-in capital of
NT$1,157 million (US$36.5 million).
Dr Carl Firth is Chairman of ASLAN Pharmaceuticals. The Company is represented by legal firm K&L Gates, and has appointed KGI Securities as the lead underwriter.
Dr Carl Firth is Chairman of ASLAN Pharmaceuticals. The Company is represented by legal firm K&L Gates, and has appointed KGI Securities as the lead underwriter.